Sign In
Buy MGNX
$4.69
+0.110 (+2.40%)
At Close: Jun 23, 2026
NEW YORK, NY / ACCESSWIRE / August 1, 2024 / If you suffered a loss on your MacroGenics, Inc. (NASDAQ:MGNX) investment and want to learn about a potential recovery under the federal securities laws, f
MGNX Investors Have Opportunity to Lead MacroGenics, Inc. Securities Fraud Lawsuit
05:30pm, Thursday, 01'st Aug 2024
NEW YORK, Aug. 1, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of stock or sellers of puts of MacroGen
NEW YORK, NY / ACCESSWIRE / August 1, 2024 / If you suffered a loss on your MacroGenics, Inc. (NASDAQ:MGNX) investment and want to learn about a potential recovery under the federal securities laws, f
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against MacroGenics, Inc. - MGNX
03:28pm, Thursday, 01'st Aug 2024
NEW YORK , Aug. 1, 2024 /PRNewswire/ -- LLP announces that a class action lawsuit has been filed against MacroGenics, Inc. ("MacroGenics" or the "Company") (NASDAQ: MGNX). Such investors are advis
Shareholders that lost money on MacroGenics, Inc. (MGNX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
02:15pm, Thursday, 01'st Aug 2024
NEW YORK, NY / ACCESSWIRE / August 1, 2024 / If you suffered a loss on your MacroGenics, Inc. (NASDAQ:MGNX) investment and want to learn about a potential recovery under the federal securities laws, f
NEW YORK, Aug. 1, 2024 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed again
NEW YORK, NY / ACCESSWIRE / August 1, 2024 / If you suffered a loss on your MacroGenics, Inc. (NASDAQ:MGNX) investment and want to learn about a potential recovery under the federal securities laws, f
Levi & Korsinsky Notifies MacroGenics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - MGNX
11:30am, Thursday, 01'st Aug 2024
NEW YORK, NY / ACCESSWIRE / August 1, 2024 / If you suffered a loss on your MacroGenics, Inc. (NASDAQ:MGNX) investment and want to learn about a potential recovery under the federal securities laws, f
RADNOR, Pa., Aug. 01, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United S
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 24, 2024 in MacroGenics, Inc. Lawsuit - MGNX
10:45am, Thursday, 01'st Aug 2024
NEW YORK, NY / ACCESSWIRE / August 1, 2024 / If you suffered a loss on your MacroGenics, Inc. (NASDAQ:MGNX) investment and want to learn about a potential recovery under the federal securities laws, f
MGNX Investors Have Opportunity to Lead MacroGenics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
10:30am, Thursday, 01'st Aug 2024
LOS ANGELES , Aug. 1, 2024 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against MacroGenics, Inc. ("MacroGenics" or
Class Action Filed Against MacroGenics, Inc. (MGNX) Seeking Recovery for Investors - Contact Levi & Korsinsky
11:10pm, Wednesday, 31'st Jul 2024
NEW YORK, NY / ACCESSWIRE / July 31, 2024 / If you suffered a loss on your MacroGenics, Inc. (NASDAQ:MGNX) investment and want to learn about a potential recovery under the federal securities laws, fo
NEW ORLEANS, July 31, 2024 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 24, 2024 to file lead plaintiff applications in a s
NEW YORK, NY / ACCESSWIRE / July 31, 2024 / If you suffered a loss on your MacroGenics, Inc. (NASDAQ:MGNX) investment and want to learn about a potential recovery under the federal securities laws, fo
After Reporting Five Patient Deaths, Data Committee Recommends MacroGenics Halt Prostate Cancer Trial
01:45pm, Wednesday, 31'st Jul 2024
MacroGenics Inc. MGNX announced on Tuesday that it reviewed data accumulated from the TAMARACK Phase 2 study of vobramitamab duocarmazine (vobra duo).
